Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Current Assets
All assets expected to be converted to cash or used up within one year.
Citius Oncology, Inc.NASDAQ: CTOR
Total Current Assets · Q2 FY2026 · quarter ended Mar 2026
Total current assets rises 63.1% from a year ago
Total current assets stood at $29.42M at the end of Q2 FY2026, up 63.1% from a year earlier and down 20.8% from the prior quarter. Over 3 fiscal years it compounded at +117.1% a year.
Context
- Total current assets amounted to 29.2% of total assets at the end of Q2 FY2026, up 9.5 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +63.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 27.54M USD
- Year-over-year change
- +151.1%
- 3-year CAGR
- +117.1%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 27.54M | +151.1% |
| FY2024 | 2024-09-30 | 10.97M | +41.8% |
| FY2023 | 2023-09-30 | 7.73M | +187.5% |
| FY2022 | 2022-09-30 | 2.69M | — |
Total Current Assets vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total current assets of $29.42M is the 9th highest of the 10 companies compared; the peer median is $57.61M.
- Its year-over-year change of +63.1% is the 4th highest of 10, against a peer median of +38.1%.
- Total current assets amounts to 29.2% of total assets for CTOR, versus a peer median of 95.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $500.78M | +672.2% | +24.6% | 98.8% | |
| Mar 2026 | $179.53M | -27.7% | -25.4% | 63.0% | |
| Mar 2026 | $82.45M | +70.3% | +16.9% | 95.0% | |
| Mar 2026 | $65.11M | +38.1% | +24.7% | 96.9% | |
| Mar 2026 | $57.61M | -22.9% | -14.9% | 97.6% | |
| Mar 2026 | $42.4M | -13.8% | +11.5% | 64.0% | |
| Mar 2026 | $41.97M | +46.2% | +9.0% | 14.3% | |
| Mar 2026 | $31.84M | -51.8% | -36.7% | 27.1% | |
CTORCitius Oncology, Inc. | Mar 2026 | $29.42M | +63.1% | +117.1% | 29.2% |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.52M | +100.5% | -12.7% | 95.6% |
| Peer median (excluding CTOR) | $57.61M | +38.1% | +9.0% | 95.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.